toripalimab + Bacillus Calmette-Guérin

This combination therapy consists of toripalimab, a humanized IgG4 monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, and Bacillus Calmette-Guérin (BCG), a live-attenuated strain of Mycobacterium bovis. Toripalimab, developed by Shanghai Junshi Biosciences, acts as an immune checkpoint inhibitor by blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby enhancing T-cell mediated anti-tumor immunity. BCG is the standard-of-care intravesical immunotherapy for non-muscle-invasive bladder cancer (NMIBC), working by inducing a robust local innate and adaptive immune response within the bladder wall. This specific regimen, being evaluated in a Phase 2 trial at Changhai Hospital, involves intravenous toripalimab and intravesical BCG instillation as adjuvant therapy following transurethral resection of bladder tumor (TURBT) in patients with high-risk or very high-risk NMIBC. The goal of the combination is to leverage synergistic immune activation to improve pathological complete response rates and prevent disease recurrence or progression.

Brand names

TuoyiZytorvi

Other names

toripalimab + BCGJS001 + BCGtoripalimab + Bacillus Calmette-Guérin-Changhai Hospital-non-muscle-invasive bladder cancer